risk pay
may four compani report well number corpor
regulatori updat convtec mark good start year whilst mix
expect think somewhat de-risk horizon
discoveri result came abcam put opportunist bid per
share reject board follow result abcam decid
pursu bid whilst number line question
growth dynam dharmacon currenc impact revenu margin
btg result line see transit period approach
competit crofab gener zytiga us
healthcar edit joinedup think seri found smid cap list
stock good exampl capit work ought compani perform
well risk pay manag get paid well dont
taken deep dive diffus larg b-cell dlbcl market assess
potenti market opportun morphosi wholly-own asset see
high bar use frontlin therapi use second line think view peer
activ space market opportun could decreas
elsewher indivior announc two legal updat first concern agreement
endo intelgenx patent litig second subpoena
california district insur cdi whilst first updat suggest indivior
protect film franchis gener second indic potenti new legal
overhang stock clinigen announc partnership bristol-my squibb
south africa think posit partner global pharma
compani speak clinigen qualiti may open opportun beyond south
africa establish clinigen distributor whole africa
north american colleagu note number updat read-across
name abbott bullish view growth diagnost set high bar
siemen healthin turnaround deep dive qualiti valu healthcar
option acceler path moln
takeaway find document
takeaway month page
valuat tabl sector perform chart page
month ahead trade idea page
versu consensu upcom result page
newsflow north america page
eu investor need know page
price market close may unless otherwis note
takeaway month eu healthcar research
may number earn report convatec trade updat
interim siemen healthin horizon discoveri btg result
alongsid corpor updat compani coverag
convatec trade updat signal solid start organ growth ahead
guidanc consensu forecast somewhat de-risk brief growth
awc line cc id deliv strong growth ahead expect whilst
follow-on impact transfer product line haina still act drag
underli growth ostomi siemen healthin interim saw small beat sale
organ adjust profit larg driven imag diagnost done
enough steadi ramp atellica placement wherea advanc therapi
disappoint much weaker organ growth adjust profit margin horizon
discoveri report offer period follow opportunist bid
per share abcam reject board ground
undervalu busi growth prospect number
line estim key question currenc impact top line
margin underli growth dynam dharmacon btg result
line number consensu solid perform zytiga
establish im product crofab think outlook mix
competit crofab possibl competitor product launch
gener zytiga us octob believ btg might look utilis
firepow sizeabl acquisit off-set said declin
taken deep dive diffus larg b-cell lymphoma dlbcl market
assess potenti market opportun morphosi wholly-own asset
think hurdl frontlin therapi high may preclud use given
peer activ space total second line market opportun may decreas
part rbc seri joinedup think seri taken look ceo
smid cap coverag paid share price perform last
three year interestingli found coverag univers exampl
capit work ought case risk pay compani
share perform well ceo get paid well doesnt dont
corpor regulatori level updat hansa medic indivior
clinigen hansa medic announc present long-term follow-up data
us-investigator-l trial upcom american transplant congress june
key highlight mean graft surviv rate shown month
post-id transplant way beyond origin month knew
line techniqu mean follow-up month answer
key question regul see long-term safety/surviv indivior report
agreement endo intelgenx pend patent litig suboxon
film whilst help defend film franchis minimis threat gener
entri end may indivior receiv subpoena california depart
insur cdi alleg made suboxon addict think
creat new legal overhang stock await updat clinigen
announc partnership bristol-my squibb south africa initi period
five year view deal partner global pharma compani
leader oncolog posit sentiment speak clinigen qualiti lead
posit provis licens unlicens medicin nich market
highlight eu healthcar research
consider frontlin therapi
taken deep dive current potenti new therapi diffus larg b-cell
lymphoma dlbcl assess morphosi wholly-own asset fit
chang target market landscap dlbcl rare haematolog cancer
patient everi year eu us patient complet cure
standard look surviv rate found outcom differ significantli
base genet subtyp diseas surviv seen one subtyp
known gcb vs rest non-gcb therefor see need new
therapi aggress non-gcb subtyp work block
induc cell death respons cancer cell wherea current soc primarili target
brief recap first aim approv second-lin treatment dlbcl
account valuat look us prospectu think
market factor valu also potenti move frontlin
us key takeaway review look success soc
gcb subtyp see high barrier overcom frontlin
question would better target non-gcb subtyp
current soc less effect see increas competit roch
celgen frontlin struggl see better target
exhibit although genet subtyp influenc treatment choic today could
becom key driver frontlin dlbcl futur
lenz et al nejm capit market estim
look peer work combin soc think agent
ibrutinib lenalidomid len polatuzimab pola combin soc
improv surviv non-gcb subtyp target signal pathway
therefor lead addit synergist effect soc
exhibit minimum addit benefit need combin soc
lenz et al nejm capit market estim yellow bar
term financi impact see two main point high bar
frontlin therapi may preclud use within second-lin therapi treatment
framework shift treat genet subtyp use second-lin think
consid activ peer space unreason chanc
demonstr improv surviv total second-lin market
opportun could decreas
part rbc seri sector report look possibl correl
ceo paid share price compani manag
perform last three year review smid cap coverag univers
go report preconcept buccan sector like smid
cap healthcar internet thought could reli align manag
compens sharehold interest turn complet
find look coverag suggest smid cap healthcar
exampl capit work ought small potenti high-growth compani
attract entrepreneuri manag risk pay compani share
price perform well manag get paid well howev case work
accord plan dont get paid well
exhibit correl ceo compens share price perform rel sector
use compani provid tsr inform compani compens data avail
term annual variabl compens found progress
clinic
develop sale ebit/ebitda pbt/ep individu target featur promin
alongsid less explicit all-in major coverag think
measur bear indirect relationship sharehold valu creation
appear correl tsr yr basi correl slip
said wonder whether short-term metric therefor best interest
exhibit correl ceo annual variabl compens tsr
also look base pay total ceo compens versu market cap
compani manag saw clear correl base pay versu
market cap correl weaken look total compens
think encourag variabl compon link
exhibit market capitalis begin last period annual report compens
compani report factset
ctec ln solid start year guidanc reiter
convatec report solid start organ revenu growth ahead
guidanc consensu estim whilst mix littl
expect potenti question profit better-than-expect direct
travel help de-risk somewhat reiter op share still cheap
hzd abcam make opportunist bid detail requir think
abcam made appear opportunist approach horizon discoveri
satisfi new share abcam reject board
fair valu horizon discoveri includ cash balanc
sheet whilst offer repres healthi premium prevail price
touch recent think scope improv note
abcam cash balanc sheet june think
compani could sweeten offer somewhat today
per share debt howev would need info abcam
intent horizon consid use cash worthwhil abcam
sharehold us see strateg overlap two compani combin
also question
moln sw pipelin progress multi-darpin ad option
lead asset abicipar data remain key near-term catalyst see
good progress oncolog pipelin whilst earli stage see valu build
moln focu hard treat relapse/resist cancer limit efficaci
option particularli differenti multi-darpin high
valu indic reiter outperform specul risk rate
siemen healthin shl gr beat imag strong atellica ramp
question advanc therapi
healthin saw small beat sale organ beat versu
consensu adjust profit larg driven imag diagnost appear done
enough good profit steadi ramp atellica solut placement
offset weaker organ sale develop view advanc therapi
howev clear disappoint like come focu full-year guidanc
look beyond horizon
first glanc abcam offer horizon discoveri appear opportunist
whilst think deal north like still see mani
variabl within highlight key questions/consider
provid initi outlin combin entiti acquisit complet
sensit accretion/dilut assum price horizon last rais
price price think meaning cost synergi need non-dilut
unless abcam offer higher proport cash combin see revenu growth
maintain see ebit margin come unless revenu
cost synergi deliv
hzd ln question see abcam posit strengthen
horizon result line see two questions/ concern investor
struggl reconcil horizon organ revenu growth number given currenc
movement think risk dharmacon revenu growth given lacklustr
perform whilst horizon clearli long-term potenti convinc
today result act strengthen hand light opportunist approach
hzd walk away
abcam announc walk away horizon make formal
offer result yesterday accompani respons horizon abcam
offer equat sale horizon board indic fair valu closer
sale line industri lead tools/genom compani see
good price disciplin abcam especi horizon manag wouldnt move
valuat intim rn think commentari horizon
manag lack overlap even analyst present yesterday
referenc lack overlap monoclon antibodi would disagre
may help also wrinkl financi investor rais
concern link could taken posit abcam sharehold
optimist could take combin group
spoken abcam manag also heard clear rational combin
two clearli price right
second sector weve look far there meaning
correl ceo paid share price compani
manag perform last three year one
internet sector given coverag healthcar sector confin
smaller end spectrum think fair argu two amongst
raciest sector consid
indv settl endo intelgenx minimis gener film threat
indivior togeth aquest therapeut formerli monosol rx enter
settlement agreement endo intelgenx resolv patent
litig relat suboxon film settlement permit begin sell
gener version suboxon film januari earlier certain
circumst term confidenti similar settlement
believ would allow earlier launch anoth gener launch usual year
later one would logic expect posit indivior continu
protect film franchis continu minimis number gener threat
look updat dr reddi teva alvogen key protect film
franchis indivior assert three new orang book patent
anda filer optimist posit newsflow time
indivior film franchis think could lead consensu revenu profit
upgrad given expect gener film launch come months/year
btg ln result line transit period approach
finish line repres solid perform zytiga establish im
product crofab howev outlook mix begin see
competit crofab zytiga revenu overal think guidanc
equat growth slowing/declin risk speed crofab competitor
uptak btg cash could make acquisit reinvigor top line
ln keep script hurdl still overcom
think circassia manag make progress build commerci
platform reduc non-essenti cost focu cash flow howev still
commerci regulatori hurdl cross invest case improv
view think share mark time see deliveri particularli
circassia target highli competit market fund risk remain reiter
indv feedback drl call
see follow takeaway indivior dr reddi call compani
confirm expect fda decis gener suboxon film product
mid-jun exact detail goal date drl manag watch wait ip
decis make decis launch given roll litig
landscap drl manag would give specif detail launch risk etc
would play hand strategi wise understand later
question manag said suboxon remain key pipelin launch product
march-y consist prior messag market perhap
inconsist talk call drl must launch risk
given new patent indivior assert think line
current view drl manag would least wait end
appeal process decid launch perhap first rule
new patent indivior assert
indv competitor refil weekli monthli depot product fda
note indv peer braeburn develop partner camuru camx-om
market cap sek resubmit nda weekli monthli inject
buprenorphin depot product fda use opioid addict
treatment yesterday januari year sparc braeburn camuru receiv
complet respons letter much detail avail
question need address assum minor delay submiss process
delay launch base month answer resubmit
confirm four ii six-month review time approv iii month
launch prepar see materi chang view term time still
product take market share long act depot space
indivior sublocad product keen hear camuru us
partner braeburn commercialis strategi particularli price rel
hmed anoth posit data point confid clinic regulatori
hansa medic put rn present long-term follow-up data
patient us-investigator-l studi american transplant congress june
key highlight mean graft surviv rate shown
month post-id transplant patient one patient
failur alreadi known per nejm paper unrel mean
follow-up way beyond origin month knew of/had visibl
almost line time-point perspect techniqu mean follow-
month answer key question regul see long-term
safety/surviv look final data highd studi expect
come month fulli de-risk clinic question albeit remain confid
given data presented/publish per last state view
mor gr consider frontlin therapi
given import morphosi invest case chang
landscap target market dlbcl complet deep dive current
potenti new therapi analysi rais question think critic answer
decid whether could move frontlin therapi see
potenti impact second-lin market consid
indivior receiv subpoena offic insur commission
california depart insur may request document relat
bioavail bio-equival suboxon film manufactur record
product compon potenti develop depend
indivior make drug addict view suboxon like almost everi
product opioid abus
buprenorphin peopl addict suboxon sure could
potenti impact everi manufactur form buprenorphin
alter tast fact ii speak compani understand
base upon activ
surpris would highlight unusu drug compani receiv
subpoena fair isnt iii rememb suboxon film fda
approv sure indivior could done extra off-set risk
california larg market indivior risk could trigger purdu
esq investig target opioid pain manufactur whilst see
news materi neg day think certainli creat new legal
overhang time difficult assess may make investor even
clin ln right tri act highlight patient need
us sign right tri act see aim improv patient
access unapprov drug build upon similar state level legisl alreadi
state authoris doctor administ drug clear phase patient
exhaust approv treatment option howev patient request
product pharma compani mandat provid legisl
replac fda compassion use polici offer fda oversight
matter remov need request approv fda
also replac centuri cure act mandat need pharma compani
outlin compassion use polici whilst debat overal impact
merit act think move highlight patient need uniqu
us leader provis servic think could posit
clin bm partnership sign south africa
clinigen announc partnership agreement bristol-my squibb south
africa initi period five year build upon long-stand relationship
compani agreement clinigen commerci medicin divis
provid patient south africa access bm product alongsid local regulatori
knowledg distribut infrastructur expertis provis licens
medicin understand transfer relev market authoris
bm clinigen complet africa asia pacif region
clinigen current specialist pharmaceut hospit med-tech licens
product gener brand activ market
healthcar valuat tabl sector perform chart
denot act broker note siemen healthin list march henc ep avail
price market close bst may
capit market estim factset price inform
companyrecimpli upsideptpricemcapevforecast growthforecast growthforecast compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate pharmaoutperform spec spec medic aboutperform spec seknanananananananananananahorizon discoverysector perform spec biopharma outperform spec partnersoutperform spec spec therapeuticsoutperform spec healthineerssector exclud morphosi salesev ebitdap eu healthcar
exhibit weight averag share price perform coverag versu ftse share
jan may
jan may
jan may
jan may
jan may
jan may
share exhibit coverag perform versu peer wider sector
jan may
jan may
jan may
medicalnmc dechra pharmaceuticalsindiviorabcameco anim groupudg careianc pharmacv groupgenuscaretech holdingsclinigen groupconsort medicalastrazenecafts sharemorphosyssmith nephewstoxx europ eglaxosmithklinemolecular partnersshirehorizon discoveri groupcambian groupbtghikma pharmaceuticalsspir care gp vectura groupbenchmark holdingssinclair pharmacircassia medicalnmc indiviordechra pharmaceuticalsi pharmaabcameco anim groupgenuscaretech holdingsmorphosysudg carehorizon discoveri groupfts shareclinigen groupastrazenecacv groupsmith nephewcambian groupglaxosmithklineconsort medicalstoxx europ eshirebtgspir care gp benchmark holdingsmolecular partnershikma pharmaceuticalsvectura groupsinclair pharmacircassia dechra pharmaceuticalshansa medicali pharmamorphosysindiviorabcamgenusudg carecambian groupastrazenecacaretech holdingsclinigen groupmereo biopharma groupconsort medicalhorizon discoveri groupsmith nephewfts shareeco anim groupstoxx europ ebtgconvatec groupglaxosmithklinecircassia pharm molecular partnersshirecv groupspir care gp benchmark holdingshikma pharmaceuticalsvectura groupsinclair pharmavernalisshield month ahead trade idea
look june consort medic result june partner
action date gener advair come june
consort result look updat pipelin especi syrina ii
financi margin improv aesica iii thought opportun
number line consensu revenu ebitda line
factset ahead ep last week consort
share price reach peak major
last deep dive note consort link outlin underli
fundament consort alongsid gener advair program
inject pipelin devic aesica turnaround improv oper
margin peer level catalyst could drive re-rat turn could
boost target
gener advair partner resubmit anda novemb
sparc guid action date june provid fda approv
product mylan/consort would first market peer hikma/vectura
recent announc fda upheld origin decis disput
process request addit clinic data mean hikma target re-
submiss potenti launch sparc
potenti catalyst timet coverag coverag peer
exhibit potenti catalyst timet coverag coverag peer
note indic project result releas date
stockjunejulyaugustabcam abbott laboratori result juli result juli abcam trade updat tbc qiagen result juli result aug biorad result aug pharmateva result aug result aug heron result aug result tbc result aug integra lifesci result aug biom result tbc btgvarian medic system result juli result juli astrazeneca result juli trade updat tbc cumberland result aug result june action date gener advair jun dechradechra trade updat tbc eli lilli result juli vetoquinol result juli result aug phibro result aug medicalhorizon discoveri abbott laboratori result juli result juli abcam trade updat tbc qiagen result juli result aug biorad result aug result juli indv result tbc pdufda date use schizophrenia juli partnersamerican societi clinic oncolog june result juli result aug molecular partner result aug societi clinic oncolog june eular june result juli roch result juli morphosi result aug result aug sarepta result aug siemen healthineersabbott laboratori result juli result juli ge result juli labcorp result juli philip result juli varian medic system result juli roch result juli quest diagnost result juli healthin result juli qiagen result juli pharmainterim trade updat tbc allergan result aug novarti result juli astrazeneca result juli result aug result late july/earli august tbc smith nephew result juli result aug coloplast result aug result juli lonza result juli recipharm result juli aptar result juli feedback fda meet track statu hansa result juli argen-x rsult aug readout month follow-up data tbc out-licens deal nda submiss result tbc
versu consensu upcom result
exhibit versu consensu compani report soon note consensu expect may small number contributor
note indic limit number contribut consensu data
factset capit market estim
stockmetricconsensu fcst fcst fcst medic newsflow item north america
north american colleagu believ key newsflow revolv around
qualiti valu healthcar abbott confid outlook diagnost read-
karyopharm molecular partner
qualiti healthcar
move toward
valu volum
growth diagnost
segment set bar
high siemen
diagnost unlik
go straightforward
frank morgan publish deep dive report qualiti valu healthcar us
discuss gener specif idea qualiti measur system value-bas
purchas transit focu valu volum think
featur key item consid everi us-expos compani arguabl pretti
much compani focus us market therefor clear understand
underli dynam us market product need deliv
consid valu add utmost import compani look launch
glenn novarro brandon henri reiter outperform rate abbott
laboratori post meet manag abbott project mid- high-singl digit
sale growth rate diagnost year look set pursu roll-out
modular alin system eu us manag prioritis invest
intern capac sale forc technic personnel abbott appear confid
placement momentum alin eu anticip similar success us
next year laid initi think level peer activ
set high bar siemen healthin turnaround diagnost base
success roll-out modular high throughput atellica solut platform sinc
abbott also market high throughput capabl comprehens test menu
make transit new system smooth possibl think messag
abbott set high bar siemen healthin lot catch
posit read-across
molecular partner
multipl myeloma
nda submiss
compel see option
acceler path
see karyopharm plan file nda selinexor penta-
refractori multipl myeloma mm request acceler approv
posit read-across molecular partner lead oncolog asset mm
selinexor storm studi singl arm penta-refractori mm patient
combin dexamethason dex show respons rate averag
durat highlight compel data indic
patient highli resist current therapi develop timelin could
shorten current mm assum data order file howev given
promis data seen far singl arm studi combin
bortezomib/dex patient respond patient progress month
rest still on-going think also possibl could see option
acceler path assum data remain compel
exhibit stock cover dougla miehm
titl link note
preview trough quarter
valeant report result morn may anticip revenu adj ebitda continu
believ compani guidanc may conserv would surpris see upward revis come
step right direct
crh report result yesterday close quarter ahead street estim view beat
due combin higher case volum ii lower anticip rate cut headwind iii commerci rate
pressur yet felt
preview kick volatil year
report result may market open confer call et stress result
come quarter like volatil consider uncertainti head print believ well
document investor surpris weak quarter
preview chang long-
dr report result market open may confer call et expect revenu
ebitda sh overal focu remain perform key center sfsh bhsh umash result
also provid glimps oper asc acquir deal
takeda shire reach agreement
expect
result weak expect focu
remain near-term uncertainti
term transact shire takeda announc reach agreement combin compani term
consist fifth propos origin announc april offer impli valu cash
takeda share term base takeda share price exchang rate ii us
april offer repres premium shire unaffect adr price shire sharehold
would new takeda adjust fx declin takeda share price put valu offer
revenu forecast consensu revenu vs forecast
consensu l/intl report revenu vs forecast brand rx report revenu vs
forecast diversifi report revenu vs forecast gi derm revenu includ
brand rx estimate estimate respect note largest posit varianc rel
forecast diversifi segment potenti due loe time investor may view lower
qualiti beat given modest perform segment
revenu forecast even report result estim
total revenu vs forecast gross profit compar estim although
somewhat disappoint place much emphasi quarterli result note compani current transit
period result could volatil said monitor cash burn come quarter
guidanc increas strong
result well consensu estim importantli compani made upward revis guidanc
expect revenu adj ebitda rais consist
think albeit somewhat sooner anticip
titl link note
obtain new fda clearanc announc receiv clearanc fda submiss
termin steril multi-channel flexibl endoscop use steril clearanc allow hospit termin
steril gi endoscop dimens within clear intend use scope fall within classif could
includ certain colonoscop duodenoscop gastroscop four less channel length intern
diamet mm greater
result street expect evid releas result like weak/volatil come
quarter follow complet also announc fda approv view latter
posit remain cautious optimist benefit could provid face geting uncertainti
gud surpris result
margin compress ebitda
miss like caus concern
ln trial progress well fsg
de trial initi expect june
quarter line reiter long-
quarter weak margin pressur
appear favour
onc announc collabor merck
northwestern univers
result knight report result morn larg line higher consensu forecast
revenu quarter consensu estim revenu y/i driven primarili
increas sale movantik time sale order impavido report ep consist
estim consensu in-lin earn despit top-lin beat part due higher-than-expect oper
revenu vs forecast dr report revenu vs estim last
year consensu factset estim revenu grew rel though expect
driven addit newli acquir asc contribut exclud impact acquisit revenu would
estim term y/i revenu growth facil sfsh grew bhsh declin osh
flat
aurinia reiter track finish enrol ph lupu nephriti trial end addit compani
expect initi two ph ii trial fsg de next month consist previou commentari result line
expect chang outlook
knight result line slightli better expect overal continu place emphasi knight busi
develop progress financi result given early-stag natur manag commentari essenti unchang
continu see attract risk/reward profil recommend share investor seek long-term price appreci
result weaker consensu estim although revenu stronger ebitda soft highlight
margin pressur expect compani face come year overal continu believ acquisit
need off-set headwind face dr
onc report result morn focu remain compani clinic and/or commerci progress along
upcom list view compani look pois make progress varieti clinic mileston
aggreg provid favour set-up
collabor merck northwestern univers morn onc announc investig sponsor studi ist
support merck northwestern univers studi extens previous report ph studi investig
reolysin combin keytruda treat second line pancreat cancer patient studi enrol approxim
patient final studi design announc upon enrol first patient expect
titl link note
safeti data surpris
onc appli list
dexamethason
abvx present data
mechan action new clinic data
expect summer
full data present wfh world congress earlier morn roch present full set data top-line data
studi hemlibra prophylaxi patient without fviii inhibitor releas novemb indic time
studi met primari endpoint surpris show statist signific clinic meaning reduct number
treat bleed time subject receiv hemlibra prophylaxi everi week compar receiv prophylaxi
notabl howev superior hemlibra demonstr earlier fviii prophylaxi
applic list earlier even compani announc appli list common share
previous approv sharehold onc also implement share consolid carri
basi one new common share everi current outstand common share consolid effect may
share expect begin trade post-consolid basi may follow consolid
onc announc research collabor keck school medicin usc morn onc announc explor
reolysin combin keytruda velcad dexamethason treat multipl myeloma collabor keck
school medicin univers southern california studi extens current reo studi reolysin
velcad dexamethason multipl myeloma addit detail design announc follow enrol
first patient expect trial enrol patient relapsed-refractori myeloma primarili evalu overal
respons rate addit safety/toler
abivax provid detail lead drug mechan action abivax present new data mechan action
hiv ulcer coliti european medic confer data suggest upon bind cap bind complex cbc
enhanc splice two type rna
segment viral rna hiv viru requir replic therebi prevent viral prolifer
long non-cod human rna upon splice result increas express small microrna potent anti-
increas splice activ produc novel viral rna speci may trigger immun recognit hiv-infect cell
exhibit stock cover randal stanicki
titl link note
question focus
earn call matter stock
fre respons complaint alleg
seriou issu level deal break
teva last sever day positioning/short cover ahead thur broader view out-year street number
high updat analysi exhibit ev/ebitda valuat premium share volatil five updat thur
could add revenue/ebitda consensu slightli us billion
fre respons complaint look enforc deal close surprisingli alleg seriou data integr misconduct
expect question constitut mac-out fraud manag knowledg enough break deal
appear clear issu question debat along timelin fre look push
look june
 motion expedit trial case
fre grant
result underscor fre want
deal like decid court
 consist tone fre
earn call trial date set juli
momentum continu solid quarter
near-term focu cms/legisl
spec pharma day agenda
grant zilretta vyxeo j-code
execut solid on-track
concern persist stock fade surpris
focus week heavi
manag meet teva
market motion expedit proceed case fre grant vice chancellor laster per review
judici action form compani ask june trial fre push trial earlier jan
releas even ahead fre result tomorrow unlik coincid adjust ebitda million
big disappoint think materi lower likelihood settlement fre motiv attempt get deal
cost even higher adjust probability-adjust target compon likelihood full price deal
listen fre earn call morn start et continu busi week merger news flow
report in-lin street expect given symphoni data maintain fy guidanc expect nomin
boost nerv block confid understand conservat busi continu measur revenu
momentum move right direct re-affirmed call near-term focu remain regulatory/legisl
updat chang view/pt
releas day agenda hcpc meet may expect thu far preliminari decis recommend uniqu j-
code zilretta vyxeo
saw solid result show strength across region guidanc move higher eventu guidanc rais
anticip larg captur strong earli updat reflect on-track restructur increas manag
confid around fundament howev still struggl long-term growth outlook hear anyth chang
view estim move larg earli restructur benefit
return multi-c investor meet teva drove fundament discuss
time volatil show sign slow follow updat fre well result move
big earn week overlap first sever sell-sid confer next five week compani within
specialti pharma sector report week four like drive attent meet manag
week
titl link note
ipxl amneal deal close
result guidanc provid
underscor import combin
receiv anda approv
link binari
spec pharma day agenda
meet releas await decis
expect updat post receipt fda
meet minut current plan
result solidli street
five thing focu look
address call
three reason stock weak
new amneal conundrum bull/bear
clear
report solid result
guidanc re-affirmed thought ahead
cc et
 spoke manag
post call thought stock weak
question
sign earli competit messag
amneal announc close deal combin morn creat new amneal trade ticker
form largest gener manufactur us product famili anda pend fda
receiv approv dicyclomin hydrochlorid decatur facil follow march approv
ropivacain hydrochlorid bring total approv anda year
releas day agenda hcpc meet may expect wait day still releas
agrx report market littl updat pend receipt meet minut type meet fda follow
twirla compani expect provid updat follow minut give better visibl around timelin
path forward could come time agrx still expect resubmiss set late action date
report first quarter new ceo announc feb revenu ep billion came
street billion deliv beat full-year revenu ep re-affirmed street sit
roughli midpoint rang billion base analysi segment chang question
call go whether implicitli point lower end rang rx lower chci rais net
 somewhat unclear
trade post deal updat guidanc brought debat larg sell-off yesterday bull case point sharp target
growth ramp bear case still link show growth pick given ebitda guid
question growth target robust given gener fundament back-drop evid pipelin convers need
maintain sp pt
report solid result revenu ebitda million million come solidli street
million million compani continu execut tough environ
share weak post report upsid morn driven question weak
total clear seen name spec pharm revers today may relat combin perceiv move
part guidanc re-affirmed compon chang discuss first take link combin back-end
weight concern around rx busi import swing factor
submit citizen petit cp date may fda link ask refrain approv nda fixed-dos
combin bupivacaine/meloxicam call name fda view far clear unexpect
like get discuss sell-sid confer week wed perhap signal competit messag
specif ask fda ensur nda includ suffici evid demonstr safety/effect address
signific safeti concern combin
titl link note
delay preliminari j-code
recommend exparel quick
physician awar build launch
on-track inflect surpris
releas hcpc meet agenda may see day day includ exparel note
delay preliminari j-code recommend exparel pend consider matter see agenda
report result provid zilretta launch updat follow manag meet late apr
overal noth surpris call tone consist posit push toward sever updat
contribut continu view inflect stori reiter outperform chang target
near-term pressur continu
focu still pipelin potenti
insi report also came separ licens partnership announc lunatu subsi middl east
tirf market continu see pressur insi still midst enact stabil plan subsi effort
asid progress pipelin remov doj overhang remain two sourc potenti valu depress stock
chang view
challeng near-term
execut one solid
reflect quarter three thing strike us continu hit number despit one challeng
posit build credibl ii compani earli aggress make mani difficult move ration
oper like help iii bigger overhang still overhang take time move past remain sector
take step back look driver
recent weak outlook unchang
share met beat sell-off stock sinc late januari part weak market-rel
clear debat form around level consum growth ii back-end weight rx outlook busi
review expect late fall anticip debat continu remain sector perform ahead manag meet
solid start year back xyrem tail
strategi deal focu high call
report solid xyrem-driven volum ad support updat back track product perform
guidanc boost modest conserv focu call surprisingli two import valu drive
relat theme around support tail growth xyrem life-cycle strategi ii potenti near-term
 nda dsuvia resubmit
fda set import catalyst
morn announc resubmit nda dsuvia fda compani expect fda accept nda
within calendar day six-month review set project pdufa date
 soft come low
expect pose top
question up-front et call
report revenu ep billion versu street billion street number
reflect ep temper came apr analyst meet link miss revenu ep number despit
temper apr help lower spend
learn
thought stock
held abbrevi earn call morn result captur first take soft come low expect
pose top question up-front et call bottom line stock back unchang manag
expect three upcom mid-year launch gener advair neulasta restasi specif given chang
gener neulasta outlook move past well advertis soft came low expect messag around
chang neulasta specif import counter concern around observ partner biocon one primari
reason move lower sinc late apr
titl link note
heavi thought post talk
report close follow earlier announc resubmit dsuvia nda consist
plan time confid around address fda concern complet respons letter high focu shift
quickli becom event-heavi sever catalyst watch potenti push stock higher
pipelin increasingli need
support valuat hurdl low pt
leav manag effect deliv chang confid messag around near-term pipelin opportun
specif neulasta messag help drive move despit low expect result quarter rais
addit question around visibl increas need support pipelin lower target remain
result come big bag
surpris interest move
implic teva cc
data come mid-year reiter
consist messag around progress
stock volatil like continu
report result revenu million far consensu million full year spend outlook
unchang view npv product stori trade updat around higher valu opportun rather
quarterli profit though direct trend revenu mostli bendeka bendamustin royalti receiv teva
matter surpris releas plan launch big bag low cost version bendamustin
alway possibl tent approv ii contract teva allow question
appear like posit low cost bendamustin market ahead gener
treanda bendamustin entri believ orphan drug exclus potenti read-
result came posit data first three studi continu pipelin momentum kmph still
discuss potenti partner apadaz announc still expect year-end howev see materi
valu continu get limit attent speak manag even view unchang
like kmph long mid-year data reiter outperform
depo today result re-affirmed guidanc drove recur queri stock volatil asid
messag around strategi move specialty/cn consist re-affirmed guidanc suggest thing track
depo ebitda still highli lever would expect share remain volatil turnaround continu
chang sector perform
rx core non-cor divestitur
analysi thought manag
met manag discuss outlook busi current review given varieti outcom
possibl still unclear conclud late fall undertaken analysi rx divestitur gross profit could look
like eps-dilut see net neutral ev/ebitda like leav option one may drive debat
catalyst slowli build
focu next sever month
report admittedli came revenu littl light similar stock today quickli pivot catalyst
list continu build decis launch big bag expect make sens npv stock may
addit catalyst introduc look focu
expect complet respons
letter proair disappoint
posit teva
close announc expect get complet respons letter gener teva proair push
ep contribut presum also ep well still expect get market
ahead next gener entrant anticip lupin delay market clearli cost compani
notifi late thur afternoon would come shortli meet manag
titl link note
focus week
gener confer lupin taro
week mark first four larg healthcar confer next includ link sever
recent primer publish individu compani bull/bear debat report look question
view hope help meet prepar final expect focu shift gener sector
attend confer look cross-read taro lupin india earn call week
gener primer structural/cycl
path forward watch
call turn bull/bear debat
posit earli feedback momentum
acceler xhanc launch well on-
takeaway expert call new
drug price propos focu
generics/biosimilar access new
read teva market color
aimovig approv read cgrp class
focu launch/reimburs
feedback debat shrink grow call
discuss primer feedback
year three gener downturn began expect recoveri prolong unlik see
anoth materi step-down
come away first public updat follow april xhanc launch execut track plan xhanc
formulari commerci live tier single-step better reiter target year-end xperienc
program help acceler launch bottom line launch momentum remain earli far solid reiter op target
yesterday research team host expert call particip trump administr drug price
propos contact us replay info
lupin report fiscal held confer call today lupin largest us player among larger india-
base pharma/gener compani billion market cap revenu quarter come north america north
american pressur remain lupin see sign stabil us sale million quarter decreas
prior year sequenti importantli lupin see signal market price start normal
point strong action product prune portfolio ration major gener player teva
sandoz start effect market lupin indic stop suppli product compani
prune think competitor also indic challeng continu fiscal
ye consist view
close amgn/novn announc fda approv aimovig erenumab coincid today pdufa date confer call
friday et discuss approv aimovig monoclon antibodi mab cgrp-inhibitor prevent migrain
first cgrp therapi receiv approv teva develop among other
spent week discuss report gener primer structural/cycl path forward watch
call turn bull/bear debat compani follow updat sandoz lupin presentation/panel
larg gener corpor off-sit host discuss channel contact view chang remain
year transit pruning/optim continu eros like stay transit like remain bumpi
increasingli think begin show sign recoveri industri shrink grow process move along near-
term concern remain struggl company-specif challeng still op-rat name activ look
get construct singl stock idea word ultim expect up-cycl improv per exhibit
report link host confer call investor fri et discuss report feedback stand
gener stock contact salesperson slide dial-in inform
titl link note
new safeti measur esmya europ
teva/agn read-through amgn/nv
call aimovig cgrp thought
reimburs botox first mover
taro hikma cross-read hikma
track gx advair taro messag
consist surpris
approv like hing disput
prac commiss european medicin agenc ema complet safeti review esmya uterin fibroid europ
releas recommend today review initi late last year follow sever report seriou liver injuri
europ prac recommend includ medicin must use women liver problem ii certain
patient may start new treatment cours provid regular liver test iii esmya use one
treatment cours women elig surgeri expect detail summari recommend
document made avail
listen amgn/nv confer call morn discuss yesterday approv aimovig cgrp-inhibitor therapi
prevent migrain approv read-through teva fremanezumab also cgrp mab lesser extent
ubrogep atogep oral cgrp refer takeaway yesterday link cgrp primer market model
hikma taro provid updat fri bring cross-read us gener remain focus read-through ou
compani highlight recent report may gener primer structural/cycl path forward
watch call turn bull/bear debat compani low-cost competit india compris
anda backlog one main theme view continu remain transitori year prune
optim continu eros stay elev messag around prune theme taro earn call
highlight need rigor evalu spend composit portfolio focus taro
hikma india-bas stride also report may miss weak us result albeit smaller base revenu stock
agrx receiv offici minut type meet fda laid difficult path forward discuss call
friday reflect materi stock weak compani disagre fda commit pursu formal disput
resolut bottom line door twirla close risk much higher lower target higher
focus week
leav gener focus week publish report mon gener primer structural/cycl path
forward watch call turn bull/bear debat compani follow attend global corpor off-
site confer call investor fri talk report takeaway channel discuss news flow pick
last week drove up-tick incom interest/quest final sever singl stock updat come
week context remain activ healthcar confer backdrop
detail primer view
headlin late last week around appaloosa earli hsr anti-trust clearanc spur question around activ refocus attent
strateg much look question provid primer investor new
stori bottom line view remain opportun unlock valu via asset sale need
other
listen back-to-back call india-bas cipla dr reddi morn call provid import color
matter sever us player includ teva detail report last week
gener primer structural/cycl path forward watch call turn bull/bear debat compani
region matter current us anda base less follow
titl link note
continu see stock path higher
thought post meet manag
met new cfo david arkowitz came on-board day ahead result overal stori remain
track continu think launch go well set materi inflect fill cfo post round
manag need focu squar zilretta launch reiter op rate
 context symphoni data
abnorm around exparel
sign point strong april
close yesterday symphoni report april institut sale data exhibit clear data inconsist april sale per
symphoni million impli consensu histor monthli data revis downward million per month
believ accur symphoni data histor reason accur indic report exparel sale
would presum anyth like glitch data
stand path trial thought
ahead expert legal call set-up
akrx/fr trial approach continu receiv steadi incom call ahead upcom legal expert call
revisited/summar background key issu got outcom remain highli binari
despit push-back continu see path close risk high potenti reward stock vs close
thought post-cal delawar legal
spoke legal expert well-vers delawar law better understand legal process upcom akrx/fr trial
outcom remain high risk binari debat continu high risk still heard anyth make us
believ deal close also high potenti reward stock versu close price sever thought post call
india-bas natco
si remain stabl earn
closer look
sun zydu read consist tone
us price environ near-term
focus week
ceo dinner india gx earn
teva potenti updat
listen natco fiscal earn call took place et see takeaway compani one
smaller india-bas gener player import cross-read due partnership gener copaxon ii
rel high us exposur competit india-bas gener manufactur remain import theme wildcard
discuss length gener primer gener primer structural/cycl path forward watch call
turn bull/bear debat compani notabl natco one pessimist compani within group regard us outlook
sector short interest exhibit period end move higher average/median respect market-
weight basi short interest increas modestli exhibit took closer look also highlight move
announc plan launch big bag version bendamustin link ii enter
second month xhanc commerci launch
morn zydu cadila sun report fiscal result zydu cadila us sale increas fiscal year
account overal revenu compani file anda year receiv anda approv launch
new product us pipelin pend anda stood quarter-end notabl us launch includ gener lialda
mesalamin tablet gener tamiflu oseltamivir powder zydu provid much specif color us gener price
environ say expect pressur continu although compani state pressur much
lower preced quarter sun largest india-bas gener manufactur sun market cap billion
far behind teva billion billion fiscal revenu us million last
year sequenti us busi account total sale compar
enter shorten week sever import updat come specif listen color addit india-bas
gener compani earn call host dinner ceo still top name look potenti updat strateg
path forward latter come week expect ahead meet chairman/ceo road final
focu like still high gener neulasta/pegfilgrastim given approach action date
titl link note
question view ahead
drill top question ahead ceo dinner week compani present apss confer follow
remain top idea favor set-up sever upcom catalyst valuat think continu compel
stock year-to-d drg xyrem trend see tailwind set bring sever import updat
area feedback/quest
primer report strateg outcom
sever takeaway call
cross-read india-bas alkem
strateg review outcom first step
three bucket view
meet road investor incom call post primer report receiv signific feedback
prepar provid updat strateg review updat could come anytim includ week ahead
confer present ahead meet chairman/ceo address five questions/top heard
last week
aurobindo report fiscal earn held confer call et last night listen aurobindo sizabl
player detail may report gener primer structural/cycl path forward watch call
turn bull/bear debat compani one keep close eye given volum launch higher exposur us
price strategi time aggress aurobindo first four notabl india-bas compani report week
also glenmark alkem torrent follow five addit updat past week cipla/dr reddi tue link natco thur
link cadila/sun fri link thu far littl chang messag prior quarter india compani
aurobindo differ pressur us remain unlik revers immedi
glenmark latest india-bas gener compani report fiscal earn follow earn call et
last night listen call messag around broader gener oper environ read competit
product updat pertain coverag
listen alkem fiscal earn call morn follow glenmark call last night link alkem rel
small grow us busi cross million us sale first time fiscal us revenu grew fiscal
prior year sequenti three common theme focu us high go away ii challeng
us continu iii fda inspect continu focu potenti headwind
announc intent sell women infecti diseas post strateg review back extens board review gi
includ debat whether platform announc surpris debat leav
today around need chang stock work expect convers continu
exhibit stock cover glenn novarro brandon henri
titl link note
manag made progress order-to-revenu convers howev believ manag invest
previous expect order remain competit support top-line growth addit weaker gm
perform led lower adjust ebitda guidanc
revenu top expect led
ktwo ww revenu higher estim consensu revenu in-lin exceed
expect ebitda came lower expect due time expens rais revenu forecast
increas price target
price
revenu growth re-acceler throughout new product launch gain traction addit
debut surgic intellig platform nass septemb continu see valu share believ remain
show-m stori
revenu guidanc lower
investor expect low go result howev anticip share weak morn
manag lower revenu guidanc owe mainli continu cynosur soft reduc price target
strong start year rais
report revenu consensu rais revenu guidanc slightli rais revenu outlook
reiter outperform rate buyer stock current level
report better expect top-lin result slight ep beat ep guidanc rais fx
afx show sign stabil ovat continu main driver revenu growth new ceo bring solid
oper expertis maintain sector perform rate price target continu view transit year
esketamin investig compound formul nasal spray target treatment-resist depress major
depress disord patient risk suicid ideat among key attribut esketamin non-invas
intranas formul facilit rapid absorpt fast onset action manag side-effect gener resolv
within hour dose drug administ observ healthcar provid improv
complianc challeng treat depress esketamin breakthrough therapi design gener commit
fda render decis within month applic file file expect
last week met manag hq overal left meet confid sustain mid-
teen y/i procedur growth believ compani earli steep part robot gener surgeri
believ day posit ew believ ew continu benefit strong us tavr
market growth due intermediate-risk penetr bsx emblem momentum still earli steep part
 gener surgeri adopt curv
titl link note
confid guidanc follow
solid ndr
non-deal road show ceo cfo took place two day report strong increas
guidanc give us confid revis outlook divestitur improv itgr growth profil sharpen
focu higher growth market serv cardio vascular cardiac neuromodul product line free
capit acceler de-lever
report result larg line expect two system sold addit compani report
itha alreadi sold three system thu far rbce give us confid senhanc launch gain
recent host non-deal roadshow ndr ktwo senior manag came away confid ktwo make
necessari invest grow top-lin doubl digit next sever year reiter outperform
expect share move higher post strong result continu gain share shoulder earli sign
emerg reacceler lower extrem addit manag allevi investor concern regard
potenti near-term capit rais suggest need addit capit time
model updat ahead hq visit
takeaway hr
believ manag abil sustain organ top-line growth execut bard cost/revenu synergi
key share perform hope gain addit comfort topic today hq
attend analyst session hr came away feel confid remain share gainer
host investor visit hq franklin lake nj left meet feel confid bard
integr track product portfolio drive sustain y/i revenu growth oper
margin time
highlight hr analyst
cabana result present hr complet data publish shortli analyst event gave overview potenti
near-term product approv pipelin ep analyst meet trial result highlight progress dual-
chamber leadless pacer altern transven defibril
question
report present key question ask manag team upcom healthcar confer
sever major confer month may june provid question follow compani
elgx ew ktwo
expect launch verb surgic robot major geograph market line expect believ
robot surgeri earli stage adopt view robot surgeri bridg laparoscopi digit
kp-rhythm studi impact
kp-rhythm studi studi object determin af burden associ risk ischem stroke
arteri thromboembol adult paroxysm atrial fibril paf key find reveal patient af
burden associ like chanc stroke patient lower af burden
medic devic consum
manag made convinc argument strategi portfolio address challeng medic
devic consum segment howev given slow growth highli competit natur market
challeng exist execut key turnaround expect maintain leadership higher growth market vision
electrophysiolog devic beauti consum
titl link note
takeaway meet
recent host non-deal roadshow ndr cfo brian yoor investor focus organ revenu growth
ep guidanc launch sever new product mr-condit icd freestyl libr alin
manag express confid guidanc abil deliv sustain durabl growth beyond
buyer stock current level
recent host non-deal roadshow ndr trxc cfo slatteri manag express senhanc launch
gain momentum potenti doubl year-end reiter outperform specul risk
rate owe trxc abil captur addit share under-penetrated market
revenu oper
margin target line
guidanc focu call
bind offer cdh
heartmat recal affect
futur sale devic
manag meet reinforc
confid high end
ep guidanc line organ revenu
growth lower rel estim
lrp target line believ capit deploy potenti driver stock upsid
percent compar cc revenu growth high single-digit cc ep growth like mid-point guidanc due
thursday estim in-lin consensu meaning appreci mdt share price current level requir
greater clariti manag strategi valu creation suitabl topic june investor day
cdh make bind offer sirtex medic var propos offer earli may
sirtex medic announc receiv unsolicit non-bind indic condit propos cdh invest cdh
china-bas altern asset fund manag acquir sirtex cash price today sirtex medic
announc cdh enter bind agreement acquir sirtex medic cdh bind offer
repres total equiti purchas price premium offer deal still condit approv
australian foreign invest review board sirtex sharehold feder court australia regulatori
fda instruct recal heartmat left ventricular assist devic lvad implant sinc
septemb accord letter post agenc websit approxim heartmat devic subject
recal began commerci sale heartmat receiv fda approv heartmat august
abt quarterli sale lvad around million
recent host seri investor meet manag manag express confid high end
revenu guidanc highlight sale would acceler level buyer ew head
anoth season strong rais pt reiter outperform
report solid finish fiscal year top forecast guid essenti line think
four segment particip deliv strong ahead consensu estim upper half organ
growth forecast realist start point set estim rise confid
manag abil meet even exceed forecast narrow discount large-cap med-tech peer rais
pt reiter outperform
incom call investor show interest med-tech remain high med-tech thesi still intact post earn
titl link note
fda approv expand indic
receiv fda approv two new
cholecystectomi doubl senhanc
indic senhanc laparoscop
inguin hernia
get sp across finish line posit expect measur roll-out sp
exhibit stock cover frank morgan
titl link note
beat solid us op uk
decent beat slight rais
out-performance conif
street concern report last week turn unwarr result slightli ahead
expect reach high end ep guidanc quarter improv perform uk foster cautiou
optim ss volum growth across pond still far short manag target due on-going nh referr issu
mitig effort appear drive increment improv saw modest ss margin expans uk better contract
labor manag despit on-going labor issu compani comp next quarter compani continu
see steadi perform us strong top-line growth carri strong price growth new januari contract oper
trend contrari result report last week although pipelin us remain full manag expect
remain sidelin larger deal leverag drop come quarter
exceed expect high end guidanc larg driven out-performance conif acceler
cost save also led manag increas guidanc sotp pt rais due increas guidanc
meet high bar high-acu
carri solid momentum new year meet expect strong guidanc year re-affirmed
sign progress difficult backdrop
volum remain challeng manag post modest ss revenu growth thank benefit price
medicar outpati rate updat benefit servic line transfer center strategi volum remain challeng
littl contribut flu season fortun effect ss swb control better fte manag effort margin
bp initi guidanc re-affirmed like updat next quarter divestitur progress one close
april six definit agreement
post beat rais
guidanc favor medic util
take-away humana inc nyse sp result exceed expect strong medicar advantag growth solid
oper perform across enterpris manag rais guidanc better expect medic util trend earli
beat consensu match estim continu recent trend solid ss admiss growth solid organ volum
growth combin higher acuiti price drove strong ss revenu growth combin strong growth led
top-line beat gross margin hospic yoy drag acquisit typic take month
reach compani averag balanc good quarter good start year afam deal close initi indic
suggest smooth transit appetit continu still appar
result line estim essenti line consensu continu experi strong momentum
track ahead manag expect earli year newli acquir facil continu ramp occup
expect along improv ss oper signific room improv facil
well recent de novo appear plenti runway organ growth next year unfortun growth
occup yet translat margin expans addit current oper stabil grow return might
possibl intermedi term could drive lt growth
beat consensu ep guidanc
re-affirmed afam close
titl link note
aet beat govern growth
beat solid op uk
solid start year goe unnot
miss advertis pharmaci
soft north america
beat momentum across
strong start year ahead esrx
aet post anoth strong quarter line manag expect exceed street estim continu
strength within govern book improv medic benefit cost upon exit individu commerci busi
reinstat health insur fee hif posit prior-year develop across busi importantli favor
develop off-set addit medic cost driven particularli sever flu season aet longer host confer call
given pend acquisit compani expect close
acadia result ahead street line manag expect quell fear behavior space
stoke earn call last week manag express cautiou optim improv perform uk
mitig effort address nh referr issu begin bear fruit segment begin comp onset agenc
labor issu began second quarter last year busi continu perform well ss top-line growth
carri better expect price made slightli weaker volum growth vs recent quarter manag remain
commit develop plan could includ announc second half even face tight labor market
post solid perform beat expect membership growth lower-than-expect medic cost
yoy comparison consist manag guidanc margin pressur due larg plan invest despit
seem gener decent quarter market react neg theoriz commentari regard
compani success partnership strategi retail market particularli exist relationship seem
call question long-stand thesi ideal takeout candid maintain sector perform rate
rais pt slightli reflect higher estim
despit decent volum growth global healthcar servic solid product growth constant currenc basi freseniu miss
earn expect pharmaci soft within north america coordin busi pre-releas specif
na revenu declin includ sever anticip headwind includ movement calcimimet drug part benefit
part move certain drug gener divestitur shiel said compani saw lower-than-expect
revenu recaptur calcimimet revenu dialysi servic busi first quarter revenu also neg impact stiff
foreign exchang headwind exclud revenu would slightli adjust basi note april first
glanc note fm divest sound physician busi order sharpen focu coordin platform
post solid result start year strong compliant ltac volum drove patient day growth lead
increas occup essenti flat bed count meanwhil irf segment post increas occup larger
irf base combin lower start-up loss drove strong margin ebitda growth likewis concentra post strong
top-line solid non-acquir growth well recent healthwork acquisit outpati clinic busi
manag grow top-line despit protract weather issu ne along continu impact turnaround
locat physiotherapi acquisit margin bp encourag expans opportun
util increas across enterpris management re-affirmed current guidanc carri solid momentum
provid nice setup balanc year
post strong beat-and-rais reflect solid execut across key busi line continu solid commerci
membership growth industry-lead medic cost trend strong contribut specialti product expect acceler
titl link note
line guidanc maintain
solid afam integr
track come guidanc
continu see solid perform core dialysi busi predict volum stabl reimburs
solid cost control addit intern busi progress toward sustain profit later year
encourag develop legisl front said overhang union ballot initi across multipl state
patient premium assist program remain like go away time soon expect compani continu use
strong free cash flow freed-up capit dmg sale repurchas stock aggress provid backstop
post solid result contribut acquisit strong organ growth almost famili merger complet
integr track manag focus grow pipelin jv tuck-in opportun guidanc affirm
solid beat vs consensu strong start busi gener perform well manag
maintain guidanc believ visibl good
news nashvil
weekli perspect healthcar
industri compani news valuat
solid print despit soft volum
acquir facil show
outlook reflect continu tough
solid quarter rais low end major
updat review
sector price perform week end may healthcar servic stock narrowli under-perform broader market
 health servic select index spsihp declin versu downtick
skill nurs strongest perform sub-sector last week acut hospit gain vs declin
prior week manag uptick vs declin prior week temporari staf weakest perform
sub-sector last week
lpnt work known headwind result third consecut year flat earn
encourag see continu progress recently-acquir portfolio improv product cost reduct initi
across organ manag review oper growth strategi remain on-going current headwind
behind could help open opportun acceler growth beyond coincident larg capital-expenditure project
wind free excess capit strateg growth invest given solid start line
expect reason expect subsequ quarter believ visibl guidanc improv
continu face signific challeng oper environ excess suppli pressur occup rate growth
made wors sever flu season weather along wage rate growth squeez margin said
sever encourag sign sequenti improv compani make increment progress facet busi
within control recent leas restructur benefit cash flow prospect result manag remain confid
outlook next three year favor demograph overtak current industri suppli issu yoy
occup growth like opinion quarter manag initi guidanc
actual result given low expect head print initi rang good enough
evhc deliv anoth solid quarter exceed street expect come slightli guidanc compani
focu oper improv begin deliv expect toward realiz save
expect acceler remaind year eventu reach manag target run-rat save
result evhc abl overcom weather- flu-rel headwind ambulatori segment amr divestitur
complet compani abl pay debt save cash growth meanwhil strateg review process
continu new develop report note guidanc estim bracket street
titl link note
beat organ growth cost
qualiti critic link valu
futur healthcar
improv work
result reflect anoth quarter solid top-line growth across busi line includ organ growth home health
hospic segment acquisit contribut recent close person care earn exceed expect
compani achiev margin expans lever effici within infrastructur off-set modest gross margin
compress segment
acknowledg polici forc move healthcar system toward value-bas purchas recogn import
qualiti critic link valu believ concept qualiti link valuebas purchas understood
appreci institut invest commun felt compel explor topic white paper background
ambiti research project conduct interview mani healthcar provid payor organ across
coverag univers includ chief medic offic chief oper offic director qualiti senior manag
member report serv good refer guid qualiti program work discuss gener
specif idea regard qualiti measur system value-bas purchas initi progress transit
healthcar system focu valu volum among topic
evhc deliv anoth solid quarter exceed street expect come high end guidanc
compani focu oper improv gain traction expect deliv ramp earn
beat organ growth
post strong result ahead expect solid organ growth home health hospic margin expans
across enterpris oper leverag on-going improv initi guidanc affirm
earli progress key initi
new manag team begin show progress oper initi begin deliv financi result
later year drive signific improv
manag take aggress action reduc cost improv margin along revenu compani
turnaround seem delay temporarili
decent despit ebitdar drag
post decent result despit one-tim headwind sever weather sever flu facil closur manag
note moder industri headwind name flat skill alo slightli lower wage inflat continu withhold
guidanc portfolio ration continu
news nashvil
weekli perspect healthcar
industri compani news valuat
sector price perform week end may healthcar servic stock under-perform broader market
health servic select index spsihp gain versu gain ambulatori
surgeri strongest perform sub-sector last week acut hospit declin vs gain
prior week manag uptick vs uptick prior week social servic weakest perform sub-sector
last week
titl link note
line strong occup
enrol tracker add
may show
outlook underli perform
evhc like strateg merit
potenti acquir asset
news nashvil
weekli perspect healthcar
industri compani news valuat
encourag progress key initi
challeng remain
result essenti line expect reflect continu oper improv seen
second half last year includ stronger occup skill mix within compani same-facil base well
notabl improv within transit cohort manag note signific oper improv among certain
transit facil texa leadership chang legend facil began take hold utah occup increas
improv manag care contract manag contend recent dip averag medicar star rate due
methodolog chang temporari compani improv oper metric best evid commit
deliv qualiti care rate expect recov compani adjust new standard improv perform
ampl liquid strong pipelin turnaround opportun appear well posit increment
intermedi term could includ larger portfolio skill nurs asset manag re-affirmed guidanc
releas medicar advantag part enrol data may ad net member
roll sinc april bring total enrol membership country-wid increas sinc may last year
reflect increas penetr medicar advantag membership among medicar elig popul year-to-d
membership grown reflect larg bolu new member join roll recent open enrol period
medicar part enrol downtick sequenti increas sinc may last year
despit start year noisi quarter character mani move part two larg pend transact
manag remain confid earn growth outlook given underli perform reiter
intermediate-term outlook normal earn growth approxim per year surpris view
divestitur sound ebit opportunist move leav compani still well posit grow emphasi
integr coordin care eventu transit value-bas purchas nxstage acquisit move fm
faster-grow home market maintain sector perform rate slightli rais target price
base earn per
take-away assum favor structur view potenti acquisit evhc portfolio posit strateg
standpoint would provid addit access point enhanc share key market improv
posit manag care payor cost-advantag outpati facil
sector price perform week end may healthcar servic stock outperform broader market
health servic select index spsihp gain versu declin skill
nurs strongest perform sub-sector last week acut hospit uptick vs declin
prior week manag gain vs uptick prior week laboratori weakest perform sub-sector last
week
still signific work done encourag progress date manag key
oper initi seem gain traction demonstr improv volum mani facil
labor cost effici across portfolio addit compani focus exchang offer address upcom matur
complet would give compani breath room work oper turnaround ration
portfolio manag guidanc call ramp oper initi take hold dont expect
multipl expans tangibl evid first step obvious success complet exchang
titl link note
sign progress first inning
turnaround long way go
enter palli care acquisit
continu work perfect storm challeng oper environ excess capac industri
exacerb intens flu season sever weather certain market result reduc occup start year
challeng remain near term along continu pressur tight labor market leas escal
make progress manag oper initi leas restructur headwind abat manag
expect build occup anticip captur full benefit normal oper environ
announc agreement acquir aspir health provid palli care state contract
extend earli tender deadlin
nyse cyh-sp announc extend earli tender deadlin exchang
offer et thursday may deadlin previous extend may may
fm recent result somewhat noisi due mani move part two larg pend transact major
overhang remain near term clear compani remain focus take advantag strateg posit
emerg opportun drive strong growth long term
sector price perform week end may healthcar servic stock under-perform broader market
health servic select index spsihp flat versu gain skill nurs
strongest perform sub-sector last week acut hospit declin vs declin prior week
manag uptick vs gain prior week ambulatori surgeri weakest perform sub-sector last week
tuesday issu notic agenc plan implement medicar demonstr project help make sure
payment home health servic appropri either pre-claim postpay review renew controversi
pre-claim review demo pcrd follow last week recommend gao extend prior author program
across healthcar sector
news nashvil
note
weekli perspect healthcar
industri compani news valuat
propos first attempt pre-claim
review process shut last year
exhibit stock cover brian abraham
titl link note
soft hiv/hcv rest look better
weak across hiv hcv product sale owe season competit dynam respect led bottom-lin miss
vs consensus- though strong yescarta uptak reiter product sale guidanc provid reassur rest
year like look better continu see share under-valued
soft quarter disappoint particularli hcv step-down share/pric pressur though like season hiv weak strong
yescarta solid biktarvi launch potenti hcv equilibr suggest still meet reiter guidanc
lower tgt updat dynam execut becom increasingli impt though lt hiv franchis health
product launch matur pipelin remain attract attribut could help outperform group
look fine
safeti signal observ higher-dos run-in portion track enter ph iii mid-year show
increas immun respons higher dose set stage registr discuss overal two key box check enabl
imdz io asset continu view under-valued advanc see consider upsid opportun
await advic fda
potenti regulatori
rel unev quarter though initi hint depress pivot design could look like continu believ
share significantli under-valued given lower-risk iv brexanolon foundat coupl major opportun success
believ recent sideway trade given temporari data lull provid opportun entri point particularli ahead potenti brex nda
acceptance/approv next step adjust tgt opex adjust
remain track mid-year nda submiss lead drug lumateperon follow pre-nda meet fda
timing/cont submiss agre upon see process go smoothli continu see good
likelihood approv schizophrenia given potenti valid readout multipl neuropsych indic year
remain posit reward/risk
chmp pushback expect believ off-set solid commerci execut continu confid gene
therapi illustr microdystrophin safeti new nch deal would view weak buy opportun ahead mid-
note two recent develop relev ph iii alzheim drug aducanumab nejm public ph iii bace
data tweak econom royalti neurimmun full data mrk ph iii bace inhibitor verubecestat
publish nejm today recal studi program alreadi fail believ languag paper interpret
cast doubt beta-amyloid hypothesis- patient bace-inhibitor substanti csf beta-amyloid reduct
avxs/novarti deal track
follow acquisit announc novarti april avx earn report unev although deal close remain
track may time-lin program continu progress continu see high likelihood deal close
agreed-upon term reiter price target reflect deal valu
titl link note
back solid exondi sale reaffirm confid revenu futur dmd franchis growth increas
enthusiasm june initi microdystrophin gene therapi readout view chmp pushback exondi rel minor
unsurpris setback remain bullish share given strong commerci backbon diversifi platform potenti
transform near-term data catalyst adjust tgt po adjust ex-u dmd gene therapi program
new document emerg thursday night flurri legal file on-going gener revlimid litig anda filer dr
reddi drl lotu cipla zydu apotex overal new letter indic lack cooper drl celg request
extens may deadlin key trial process june gener except drl agre
delay base case
solid quarter clariti ozanimod help diminish nt uncertainti lt diversif remain import face
out-year mm patent cliff like remain focu solid commerci execut remov worst-cas ozanimod
scenario tabl help path toward restor credibl greater recept investor given persist
disconnect valuat risk-adjust futur cash flow remain buyer
celg provid clarif today file timelin ozanimod ms note delay place file note
compani slide deck provid new inform characterist metabolit recal present
substanti amount anim respons drug activ select potenc previous report
look gener similar parent drug ozanimod slide deck reveal believ first time
structur similar half-lif much longer day
ozanimod clariti
commerci execut sign
solid commerci execut welcom ozanimod clariti could start turn sentiment around though pipelin slippag
increas spend reflect work still process reinvent celg diversifi post-revlimid next chapter compel
valuat given mt growth prospect strong expect cash flow remain buyer though revis top pick outperform
pend pipelin revlimid ip visibl would expect favor stock perform align prefer
look meet
pbc growth remain posit
aldr like updat bla timelin earn call tomorrow believ clariti remov signific overhang
catalyz stock appreci light high recent recept epti profil cgrp class doc recent posit
follow-up ph iii data strengthen management team signal activist involv believ remain signific
valuat disconnect epti favor risk profile/mkt oppti aldr share current trade see ampl
opportun gap close would buyer see particularli opportun entri point ahead tomorrow potenti
earlier today american psycholog associ confer present poster phase ii studi
mdd includ detail patient baselin characterist data show treatment effect day
day post-treat data confid treatment effect seen studi real
replic ph iii agent highli competit profil enabl multi- futur sale reiter outperform
though ocaliva demand remain flat newly-issu guidanc suggest pot inflect pbc volum
ex-u commerci success follow label updat remain confid come easl pot posit data
regener believ share remain under-valued base pbc oppti nash upsid adjust tgt
titl link note
solid quarter remain track on-going studi today stock weak potenti relat higher opex
expect due pend merger expect share trade merger dynam nt howev see potenti upsid
catalyz data believ high po
epti bla file timelin slip slightli importantli major delaysa concernand encourag reassur
underli data issu last step success pk compar studi would expect file
launch competit profil enabl out-year revenu larg migrain prophylaxi space
continu believ underappreci adjust price target
earli gaug end-us heplisav-b demand initi launch metric look promis support out-year expect
solid revenu foundat remain track meaning data believ reaffirm
agonist potenti catalyz upsid continu like reward/risk remain buyer share
support mavyret strength
report mavyret royalti line on-going strong launch increas pt hcv model
updat given higher annual base revenu like entri higher royalti tier current estimate hcv see pot
nash/pbc fairli price share though early-stag rsv hbv asset could provid add upsid addit
follow earn link receiv numer inbound reason share weak believ may
relat back-calcul royalti tier hcv franchis suggest higher-than-expect tier cutoff current
assum tier everi cumul annual sale describ learn read line yesterday
earn well recent ndr management base scenario discuss find undisclos royalti
rates/ti key unknown materi impact valuat gain clariti come quarter hcv
revenu build royalti assumpt page view share fairli valu hcv royalti floor pipelin potenti
report first quarter slightli light sale though reiter guidanc believ primari focu
turn sma program earli clinic biomark signal look promis clearer signal activ
data readout throughout rest year would gener enthusiasm/upsid pt model chang
await multipl cf catalyst near
term start corrector
look ahead data regulatori
pti continu march toward data-rich year number larg line continu like preclin valid
earli clinic signal multipl shot goal pti cf platform believ posit lung function improv
upcom readout would lead signific appreci though asset rel earli cf space
competit see attract reward/risk share
event promis selinexor result penta-refractori mm receipt track statu outlicens kpt-
much recent newsflow major news earn call clinic program remain track believ
selinexor success carv nich penta-refractori mm good opportun expand larger indic combo
ultim dlbcl look toward nda file mm add trial readout year clariti selinexor
potenti role treatment paradigm pt model chang
titl link note
trump much await drug price speech final occur polici laid discuss extens lead
speech see american patient first blueprint trump larg stick script surpris emerg
outcom consist prior view link link polici would rel limit neg impact enact
administr along end earn serv clear event enabl sector momentum link link
takeaway management
recent road vertex manag team sens rapid progress made tripl combo ph iii
enrol pricing/reimburs situat look stabl non-cf pipelin asset progress focu continu
see upsid opportun believ well posit lt revenue/earn growth remain strong competit
reaction today azar speech context
around part impact
host call hc polici lawyer/lobbyist discuss trump administr recent propos drug price assess
like implement determin large/mid-cap biotech may most/least affect contact us
transcript/replay info overal see least potenti impact see neutral impact expect higher
impact celg still rel despit consult note strident tone
come secretari monday speech well recent event definit crystal shift attitud among
policymak citizen toward escal prescript drug price expect realist effect polici compani
within space rel modest long term price share alreadi
morn report data ph iii studi galcanezumab cgrp mab cluster headach indic addit
migrain pursu aldr current pursu cluster headach mab eptinezumab time
look toward safeti data lli cluster headach studi potenti implic cgrp class overal
given efficaci safeti observ migrain ph iii aldr competitor continu see high likelihood approv
given mechan though believ still linger concern potenti cv side effect block
compensatori vasodil concern emerg ph iii migrain studi given cluster headach patient tend
greater intrins cv risk factor tend occur older male smoke histori concern safeti signal
class could unmask lli studi
heard overwhelm investor concern regard trump drug price propos continu view clariti
overhang remov gotten question potenti impact certain part drug move part someth
cover depth anoth speech secretari gave morn opportun listen overal
view low impact cover compani requir mani year develop unlik implement
ultim would see impact celg respect part drug convert
part -- someth like alreadi account discount valuat
even abstract report per-protocol orr cr updat data larger cohort
melanoma patient believ meet bar expect suggest activ open-label combo studi remain
difficult contextu given differ pt characterist denomin vs histor studi total pt data expect
well detail surround two differ dose regimen could shed light go-forward plan probabl
success remain posit share continu believ heplisav-b enabl solid floor success would lead
upsid current valuat
abstract releas even relev new data univers discuss
detail separ note updat car-t safeti durabl data celg program mostli absent
abstract need wait abstract increment impact includ detail celg ph iii studi
revlimid fl pomalyst r/r-mm kpti selinexor advanc de-differenti liposarcoma seal studi result
titl link note
fda shame list post unlik
learn fda commission scott gottlieb drug shame list post fda websit link take
recent scrutini potenti innov game tactic prevent potenti gener entri step call specif
compani product within univers note celg among manufactur list though
effort maintain public concern biopharma role high drug price potenti anti-competit practic
creat neg optic compani see minim impact list actual gener risk
buy-sid survey show trump/azar recent drug price polici propos in-lin better expect
biopharma particularli among generalist initi view potenti impact -- part b/d shift increas
medicar part negoti leverag -- also seen least like implement howev appear result
meaning improv sentiment plan posit within biotech sector indic bounceback addit
pipelin success like remain import help catalyz money flow back space
selinexor/dara/dex combo show improv efficaci refractori mm increment increas patient number eha
abstract relat stomp studi describ result differ selinexor combin notabl updat
combin selinexor daratumumab dexamethason sdd total number evalu patient increas
last year orr dara-nav patient dara-refractori patient sd pd
total orr eha abstract calcul slightli previou report continu
suggest addit activ top dara good combin
approv aimovig cgrp antibodi clean label palat price view repres key de-risk event
aldr lead cgrp mab eptinezumab expect launch drive increas excit differenti pure-
play cgrp compani aldr aldr perspect today news remov concern potenti revel
unknown class safeti concern believ price point set enabl good patient access adopt
class startfavor aldr ultim later entri larg market differenti product continu see
signific appreci opportun aldr share
follow deep dive mechan preclin data competit landscap market oppti gene therapi duchenn
muscular dystrophi dmd increasingli enthusiast potenti microdystrophin program
likelihood report favor initi nt result drive substanti stock upsid rais tgt would
buyer ahead data
follow aimovig approv call take opportun updat cgrp market model avail upon
request precis list price though net price remain unchang addit note emerg detail
reimburs particular like lack need botox step-through price-point overal minim util
criteria cgrp class among migrain patient fail prior tx
report emerg friday ema investig previous unknown potenti birth defect risk associ dolutegravir
perform in-depth ae analysi investig avail data necessarili confirm potenti relationship
dolu integras inhibitor class birth abnorm believ emerg caution express hh ema
could stimul uptak biktarvi newly-diagnos hiv pt potenti switcher continu expect
biktarvi beat current level see substanti upsid opportun given potenti hiv bounceback reaffirm
franchis strong foundat littl valu pipelin baked-in despit near-term late-stag data
titl link note
weak news former bd
head exit unfound
drive toward cure takeaway
receiv mani question today regard weak relat news articl discuss departur celg former bd
head georg golumbeski retir april come surpris investor see weak
unfound understand base convers compani linkedin info rob hershberg alreadi
run bd year april wherea georg golumbeski transit strateg role near
end career celg discuss prior year rob hershberg base seattl
respons recent juno impact biomedicin deal given transit work time
see relat report emerg today proxim upcom readout otherwis
like juno
opportun review detail week lancet public ph ii studi ipf new result
analysi provid support drug potenti activ safeti remain clean though remain difficult interpret
limit studi whether benefit real also note releas top-lin result larger/long ph ii ipf
studi result open question regard degre fibrosi benefit still emphas consider regard
overal competit landscap ipf add clariti ph iii year away see filgotinib potenti fairli
price reflect sector perform rate though share high trade potenti near-term catalyst
high-risk low-expect cf data low-risk initi filgotinib uc/ra readout may becom favor
nash data competitor cover expect come days/week receiv mani question
investor look toward upside/downsid data perform detail analysi avail data date
see greater probabl upsid scenario best-cas stock scenario competitor data though
continu look clearer ocaliva rx growth pbc improv potenti floor come multipl easl datapoint
believ support oca likelihood ph iii success remain bullish reward/risk regener readout
would buyer
morn announc licens agreement antengen exclus develop commerci lead
candid selinexor eltanexor verdinexor china asian region deal includ up-front payment
addit potenti mileston payment double-digit royalti sale help provid non-dilut capit
despit recent upsid favor storm studi selinexor penta-refractori mm continu see room
addit appreci level would fulli reflect selinexor opportun across hematolog indic
attend celg annual deep dive seri time focus multipl myeloma compani discuss overal strategi
earli pipelin next-gen celmod bcma-target asset diseas acknowledg time
event may coincid near-term investor focu compani execut commerci late-stag develop platform
found celg robust mm foundat progress toward function cure reassur potenti heme/onc sale post-
revlimid numer shot goal addit believ compani asr announc today receiv posit
investor help provid price stabil share bolu key mid-year catalyst could begin turn sentiment
spent time road sage management team sens program remain well track remain bullish
long-term opportun depress disord indic medium-term opportun iv brexanolon
post-partum depress come meet believ next clariti high-po acute-us ph iii plan
file accept potenti launch brexanolon data de-risk stori lead stock
appreci level reflect multi-billion dollar lt opportun forese novel emerg neuropsych
titl link note
prioriti review set acceler path
clinic hold sickl cell
limit impact
readout impress data
yesterday morn host call founder presid institut clinic econom review icer
independ research organ increas influenc biopharma sector publish valu assess report
prescript drug discuss value-bas price model implement see futur use
icer drug price benchmark came away clear sens icer research increasingli util negoti
leverag mani stakehold involv drug price particularli state privat payer brand drugmak like
continu need compromis cost contain feder govern unlik immedi influenti
announc morn iv brexanolon accept fda prioriti review pdufa date decemb
though entir surpris view fda grant prioriti review increment positiveendors unmet
need uniqu efficaci profil believ lead high likelihood ultim approv believ
fda request adcomm add meaning risk approvabilitya believ adcomm like reflect novel
mechan administr one-tim iv imagin use discuss schedul durabl vs data
defici would preclud approv view recent stock weak unfound believ clariti ph iii path nt
allay concern may interrog multipl dose long-term safeti key program
afternoon partner crispr crsp announc fda place clinic hold ind
sickl cell diseas hold ind stem certain question aros fda review ind though
precis question yet provid vrtx/crsp time though believ investor becom attun
diversif strategi extend revenu growth long term cf franchis matur given earli stage
crispr gene therapi program setback impact valuat continu see multipl opportun
program plenti time pipelin matur diversifi beyond cf long-term believ share
under-valued cf opportun alon
strong data continu accru filgotinib primari valu driver glpg impress psoriat arthriti ph ii result
advanc uc follow interim analysi continu see potenti out-year royalti believ
upsid opportun concentr risk somewhat balanc share alreadi could see add increment upsid
recent deep dive equiti strategist lori calvasina recent hold trend long larg cap fund
reveal celg exit stock posit past two quarter believ underscor erod
confid compani experienc last sever quarter remain seen trend signal bottom
encapsul neg tone alreadi surround name analysi suggest diverg outcom stock similar
situat continu believ fundament warrant higher long-term valuat see visibl toward newsflow
asco/car-t luspatercept settlement could potenti catalyz improv sentiment
share current trade discount multipl vs larg biopharma peer despit similar better growth prospect
major medium-term patent cliff analysi suggest stock bake littl pipeline- impli valuat floor
strong rx metric indic bounceback like foundat hiv franchis sever pipelin event horizon
see near-term upsid catalyst share believ repres attract valu money potenti return
lg-cap biotech space sentiment turn around see compel buy opportun
titl link note
share trade morn base posit data nash competitor preview scenario
readout last week note provid perspect today data
roch put statement sma commun base efficaci data formul challeng high hurdl
diseas discontinu develop drug olesoxim explor sma remain strongli
commit sma commun develop recal partner
through develop
glpg cf tripl combo
karp -e diem final seiz
day new bd leader
see indirect posit read-through develop past hour
view compani could potenti interest acquir partner aldr point
entrench migrain space botox pursuit oral cgrp antagonist lack late-stag cgrp mab
pure focu neuro need bd augment late-stag pipelin lower-risk asset vs aducanumab
glpg ph ii tripl combo cf studi potenti corrector post clinicaltri gov
avail glpg previous report multi-cent europe-bas studi initi late-april
evalu pt lower dose ad anoth two week pt homozyg
het/min higher dose ad add two week
given view import extern partnerships/m expand pipelin lower-risk asset especi given
matur potenti competit commerci franchis view today announc hire daniel karp experienc
pharma bd execut lead bd effort step right direct high financi bar could remain hurdl given current
smid-cap valuat continu believ higher-impact deal even premium would help provid comfort around lt
growth unlock valu
exhibit stock cover kennen mackay
titl link note
volum cost look
alreadi ahead st estim
despit neg read competit
guid guid put question
download day takeaway
mackay biotech takeaway
download model updat reduc
price target out-year dcf
headlin remain buyer weak
yesterday market hour novarti nv present updat data brolucizumab hawk harrier wet age-rel
macular degener studi associ research vision ophthalmolog arvo annual meet
morn regn/sanofi sni announc praluent net price reduc exchang improv access
agreement express script esrx design praluent exclus nation prefer formulari
live cover esrx cover commerci market custom use nation prefer formulari
report cabometyx cabo sale vs st expect script analysi suggest
cabometyx sale impli impress annual run-rat addit demand-driven growth account
end march price hike alreadi significantli ahead annual st estim rbc bullish estim
report in-lin top-lin revenu vs st beat bottom line non-gaap esp vs
st notabl us eylea sale post surpris beat come vs st estim
see zejula revenu light new guidanc put guidanc risk see ad competit headwind
reduc fy zejula estim prior st low well guidanc result new
price target prior st low
attend day came away posit toward compani intern pipelin engin detail
broad idh franchis develop strategi on-going pivot trial pkd addit drug discoveri effort
metabol immuno-oncolog rare diseas updat model reflect financi trend result
increas pt
neutral ad kol note elig patient dupix though remaind want system therapi
ophtho kol saw eylea competitor brolucizumab dri effect edg despit non-inferior vision effect tsro posit kol
cite zejula favorit parpi given robust data set view studi investig neg kol prefer zejula
oc mainten base longer experi mainten posit kol view forward trial success
like mirv forward ii combo data date neg kol outspokenli neg neratinib risk/reward profil
early-stag breast cancer neutral gyn onc kol like tisotumab cervic cancer breast kol concern
surround tki breast cancer although like tucatinib design would like drug remain low
eylea sale exceed expect continu see core eylea dupix franchis pressur
long-term increas competit eylea dupix reimburs pushback dupix account
evolv near- long-term dynam revis eylea dupix downward estim result price target
declin
epo offic action provid opinion soliri com patent unsurpris media report indic european patent offic
epo reject soliri composit matter com patent would provid exclus extens howev
clarifi epo issu neg preliminari opinion set date oral proceed upon request held
feb offici decis uphold reject applic made possibl subsequ appeal
titl link note
remain oc launch execut
continu like launch rubraca mainten oc despit crowd landscap given potenti edg
broad data vs lynparza safeti vs zejula see potenti acceler approv pathway brca prostat cancer
potenti enabl diverg competit crowd oc space
continu execut bla
continu like commerci see addit present european academi allergi
clinic immunolog eaaci confer later month continu build awar surround efficaci surprisingli
mid-year luspatercept catalyst focu
continu see luspatercept primari driver near-term valuat follow recent pullback see improv
risk/reward medalist md believ beta-th mid-year trial read-out addit upsid potenti
neuromuscular program sotatercept pah
pt pipelin ahead hemea updat
sale line w/ st nala timelin
luxturna commerci launch saw patient treat slow start line st estim see potenti
increas given treatment center expans payer traction focu turn hemea data updat assess
competit vs updat model add spk-gaa pomp sale potenti model increas pt
nerlynx sale line st estim growth track meet guidanc increas
conserv ramp-rat see potenti nerlynx q/q growth put annual sale within corpor guidanc
though concern follow recent nccn updat nala read-out keep us sidelin
remain critic year hif-phi class read-out competitor potenti help de-risk class
potenti transform anemia field continu execut enrol complet goal innov
protect trial data read-out anticip
blaze glori
upsid case limit reduc pt
morn rog/exel announc trial fail show benefit cotezo vs stivarga reduc pt
pull cotezo sale estim recent investor survey suggest downsid buyer weak
screen inexpens sale estim potenti grow product
friday fda adcom discuss achondroplasia drug develop larg agre futur strategi similar vosoritid develop
plan date well consensu achondroplasia endpoint line vosoritid on-going commentari public
forum highlight burdensom co-morbid function limit beyond diseas hallmark physic appear
indic high level unmet need await addit vosoritid data better understand effect beyond growth veloc
report earn provid updat compani develop program like asgct
anticip announc registr program asgct focu durabl reduct
biomark csf/urinari heparan sulfat well potenti sign stabil neurocognit
declin expect mps-iiia/b patient
recent ad one prefer stock superior pk oraxol could enabl signific efficaci
safeti benefit vs paclitaxel on-going metastat breast cancer trial see potenti earli success mid-
year interim analysi well posit build oral chemotherapi platform
takeaway fda achondroplasia
clinic updat plan focu
download model updat oraxol
interim analysi key focu ahead
titl link note
us epo biosim add headwind
esa franchis impact limit
favorit follow
quant/momentum sell-off reveal
read focu
dupi success adolesc expect
takeaway abstract
fda rld list includ kuvan
gener entri alreadi expect
updat highlight unmet need
rdeb durabl
target low price increas
morn announc studi evalu hemophilia gene therapi valrox higher dose
patient pre-exist antibodi vector dose first patient
today fda approv retacrit biosimilar epogen epogen-label indic anemia relat
ckd chemotherapi use zidovudin hiv recal retacrit approv delay receiv june
manufacturing-rel issu today approv remov overhang appear posit enter market given
epogen patent expiri resolut vs epogen litig feder juri award damag pre-
one prefer name coverag follow recent sell-off ownership data
updat today suggest sell-off attribut momentum/qu account decreas hold follow exel
miss opex guidanc street estim continu see fundament intact see scarciti valu
profit smid-cap oncolog compani best-in-class asset cabozantinib
believ transform catalyst-rich year obsv upcom endometriosi top-lin end
nolasiban regulatori path forward nolasiban live birth follow-up data initi safeti efficaci interim data
prolong studi
morn regn/sanofi report top-lin result dupix dupi atop dermat ad studi adolesc age
posit result unsurpris given dupi experi approv adult ad larg bake valuat
alreadi probabl success model result indic clinic meaning efficaci benefit via skin clearanc itch
improv view warrant approv gain commerci traction
 idh combo azacitadin show favor toler though synergist efficaci remain unknown
morn fda releas list refer list drug access inquir access includ kuvan
remind effort fda public activ effort brand manufactur limit abil gener develop
access drug sampl conduct bioequival studi mandat fda gener entri
today updat data trial rdeb present asgct present detail signific
unmet medic need rdeb burden healthcar system bandag alon rational abeo/stanford
autolog ex-vivo gene therapi approach vs methodolog detail patient specif clinic efficaci durabl
patient report outcom data mediat wound heal remain impress patient experienc wound
heal wound mo mo in-
line abstract see note
aimovig expect fda approv came yearli price anticip could improv reimburs bolster
amgn/nv lead within cgrp class rais pt account favor dynam potenti improv aimovig
titl link note
mps-iiia updat resolv
durability/neurocog qs add
today asgct present updat data trial mps-iiia updat controversi
neurocognit score data seen world symposium link note though updat longitudin csf urinari heparan
sulfat hs biomark data liver volum data deep brain architecture/volum data caregiv report observ
market read tsro/clv
asgct updat continu
show promis proof concept first
increas competit
buyer pullback rx
palynziq approv larg bake
price add pt
azn report earn lynparza sale us beat street estim us sale repres
q/q growth q/q growth though competit read-through tsro ovarian
cancer market complic fda approv lynparza brca breast cancer us sale indic
becom difficult distinguish continu growth ovarian vs addit sale come breast see today azn-rel
weak tsro share unfound
friday market close present updat data mps-iiib updat increment select
data first patient dose lower dose cohort overal biomark reduct show sign
durabl normal though effect plasma heparan sulfat hs saw slight declin time
reduct day declin reduct day nonetheless overal effect vs key biomark indic
naglu enzym activ report occur higher rang normal look toward futur present
long-term data patient well addit patient enrol higher dose cohort assess
durabl biomark reduct dose-depend reduct neurocognit stabilization/improv
morn roch present full data hemlibra studi hemophilia hemea patient without inhibitor
assess hemlibra dose respect dataset strikingli mirror hemlibra prior experi hemea inhibitor patient
expect showcas hemlibra potenti disrupt factor replac market reduc treatment burden today data
highlight hemlibra superior vs prior fviii prophylaxi demonstr viabil conveni dose taken togeth
hemlibra emerg hemea paradigm could diminish unmet need potenti patient recept toward gene
morn present long-term valrox hemophilia hemea studi world feder hemophilia
wfh annual meet fviii express level declin long-term follow-up higher dose
lower dose potenti creat durabl concern weak share
share trade today releas april total prescript data symphoni howev per review symphoni
data equival april im data appear symphoni total well im impli declin march
april seen im data thought new execut hire yesterday market close hire former sell-sid
analyst andrew peter compani new vice-president strategi receiv multipl inbound investor concern
hire potenti impli aim invest expand busi intern discoveri effort busi develop vs
open acquisit
palynziq fda approv lift key overhang focu shift toward commerci execut realiz
palynziq potenti larg market opportun remain conserv execut target commerci strategi
initi traction stem success transit currently-tr clinic trial patient commerci product
titl link note
updat model reflect
benefit weekli im script
eaaci updat consist
ec approv set posit
rubraca expedit oc mainten
morn announc reorgan follow program discontinu expect initi
concentr develop effort parkinson diseas attr amyloidosi pre-
clinic neurosci drug discoveri part celgen collabor see reorgan appropri though continu
remain sidelin given high risk high reward natur develop lack proof concept earlier
lenvima approv delay increment posit prospect yesterday eisai merck announc fda
push back lenvima snda pdufa month aug vs prior may allow addit time review
applic detail provid note lenvima pivot data reflect studi vs soc
nexavar indic lenvima non-inferior os vs despit superior vs
takeaway today present palisad data eaaci confer late-break present data
consist prior report aaaai reaffirm profound efficaci broad popul well immunotherapeut
effect vs key biomark remain posit toward approv commerci prospect await addit support
data rams real-world safeti toler studi palisad follow-on studi ahead us bla file
eu approv oc treatment set stage expedit approv much larger mainten set
standard vs expedit review
takeaway today market close announc fda accept snda file mid-march
pdufa action date jan pdufa date impli standard review period come later vs
expect prioriti review period
credit belong man arena
initi outperform price
success execut strateg pivot away belviq focu sever lead asset high probabl shot goal
blockbust market see larg de-risk etrasimod ralinepag attract acquisit target larg
exhibit stock cover georg hill stephen hagan
titl link note
bend curv make
busi case cvs/aet
squishi even softgel result
report attempt make busi case cvs/aetna merger estim combin compani use
benefit steerag tool reduc healthcar cost bp per year believ conserv assumpt
target medic use case cvs/aetna busi impact
report solid result despit lacklust perform softgel segment larg due transitori issu
biolog segment remain track compani look take share rapidli grow market
rapid respons result
report result ahead expect consensu ep beat consensu main
differ report ep model decis add back aetna-rel debt
better fear earn
amerisourc report result line expect oper incom view better fear
investor given continu challeng pharmedium gener drug price trend
make room iqvia tout
next-gen strength result
wait altar bring
deliv strong top bottom-lin result compani continu see sale success next-gener cro sale
model investor may wait sever quarter though see sale inflect faster revenu recognit earn
esrx report result essenti line expect guidanc unchang exclud impact
share repurchas program suspens follow announc merger
got wheel drive result
macro may share
report result beat estim consensu driven stronger-than-expect result pharmacy/ltc
segment share howev weak believ technic issu put unusu sell pressur stock
spi game decod ring
report weak guid soft end market delay va deal
titan dont mean movi
weak outlook sink share
report ep miss inventori write-down cordi busi relat tax expens revis
guidanc downward compani also outlin sever headwind make us pessimist growth
third time charm result
allscript report slight ep miss unlik hcit vendor re-affirmed guidanc solid book
anoth friday risk rebat
friday freak inbound call/email volum spike afternoon investor becam increasingli concern existenti
risk drug suppli chain econom tie scott gottlieb recent comment question brand/specialti drug busi
model provid hefti drug rebat exchang formulari positioning/market share fear govern could pull
safe harbor activ determin rebat kickback rebat arrang continu
non-zero probabl could occur view likelihood low believ next week govern address drug
titl link note
make offer athn
buy special specialti asset
athenahealth sharehold elliott manag made cash offer acquir athn offer price per share elliott
alreadi own stake athn share deriv elliott note could substanti improv offer price
addit privat dilig expect athn board resist initi offer premium volatil athn share
appear low offer price would week high athn share offer rang reflect price-to-earnings multipl
base ep estim ev/sal multipl revenu estim believ offer
elliott could also attempt draw bidder athn push sale strateg acquir elliott note
parti also express interest athn
fred inc announc today reach agreement sell specialti pharmaci busi million fred
acquir entrustrx busi singl pharmaci locat march million time annual revenu
million given growth specialti drug scarciti scale specialti pharmaci asset sale declin
asset valu sinc surpris believ reflect declin specialti busi fred overal fred busi
challeng expect acquisit materi financi view transact posit add
modestli scale grow specialti pharmaci segment
continu execut well deliv result ahead forecast benefit part fx rate oper margin
forecast larg mix remain sector perform rate valuat overhang ftc complaint
escap dc fear trump speech
rebat weigh share
esrx share fallen last two week rise investor fear around regulatori reform impact rebat
model weigh share still see compel risk/reward profil share balanc year tie
crystal ball gaze note hlth
wilki wont va set decid
ground hlth recent attend chair sever panel inaugur hlth confer bill look
futur healthcar multi-day event impress list speaker attende public privat
compani key theme confer consumer valu deliveri healthcar press need contain cost
growth chose attend session evolv role employ healthcar market evolut care deliveri
coverag univers short interest decreas two-week period end term total share weight
averag basi share short percent float substanti larg cap healthcar averag
reflect fear neg revis head earn investor gener increas short posit drug distributor like
part due cardin mix messag head earn season trim posit pharma servic given gener
weak share perform sinc earn investor short distributor especi reward
va cfo jon rychalski told senat committe appropri va make decis whether act secretari robert
wilki sign ehr contract may almost year former va secretari david shulkin announc
va intent reach agreement view deadlin posit uncertainti around time weigh
share addit parti sign contract think feasibl hit guidanc
still includ contribut contract
titl link note
slow block deliv soft
margin expect catch
report solid headlin number larg benefit tax reform fx tailwind off-set weaker margin
despit margin compress believ well-posit meet grow demand earli stage work expand margin
signal trump speech
struggl dod new va outlook
eye albertson
look like depart
april
initi read trump administr provid media preview speech drug price schedul et
today outlin speech larg follow theme preview administr budget recent
public appear head hh fda believ outlin could provid relief drug suppli chain
propos chang look manag unlik major impact profit detail actual chang still come
surpris speech alreadi preview could neg look administr
push chang would upend entir system
bluster continu presid trump hh secretari deliv highli anticip drug price speech friday afternoon
continu attack drug manufactur middlemen high drug price actual content limit comment
trump indic understand sector limit hh releas complet overview blueprint near-
term action area solicit feedback posit hh document pbm
sponsor includ bring privat sector pbm negoti solut medicar part market includ give pdp
opportun experi valu base reimburs indic base price formulari strategi mid- year chang
loosen protect class drug power negoti manufactur
friday even politico publish stori detail april report dod dod outlin issu
implement mh genesi project state washington politico specul find could
delay sign va/cern ehr contract report cite critic sever incid report three site
washington delay implement system fourth site though concern note review
conclud month ago sinc dod conduct pre-schedul break deal implement
interoper issu host two earn call analyst day issu discuss
hear beltway perspect host call former senat financ committe counsel colin roskey whose year
healthcar law polici experi includ extens work privat public sector mr roskey provid perspect
presid trump speech friday hh secretari azar follow-up speech yesterday document titl american patient
first detail ask feedback variou polici propos impact propos chang administr
plan requir congression action make non-start near term
investor day present continu indic move drug purchas wbad
purchas organ earli believ movement albertson safeway drug purchas wbad
util drug distribut would neg current distributor posit
indic contribut approxim billion revenu ep
 neg ep estim estim declin approxim billion revenu
store sale lower rx revenu ep estim albertson would approxim
billion revenu higher margin would contribut ep aggreg estim loss combin
busi could neg ep busi move away
retail volum slightli april iqvia npa retail-level prescript data april show adjust volum
y/i basi script dispens retail mail data repres modest
neg suppli chain start slight y/i volum growth larg due flu
sign ehr contract
bunker updat ahead
va announc afternoon statement act va secretari robert wilki sign contract
implement new electron health record system contract cost ceil billion year essenti in-lin
expect note appear prime contractor va implement also consist
expect expect contract ramp year gener billion annual revenu sever
year contract beyond year implement period suspect signific recur revenu stream
host manag meet investor week nyc continu see one
compel long term risk/reward profil coverag univers best posit capit trend toward vertic
titl link note
iqvia share drop fda highlight data
noon iqvia share drop within minut fda report fda scientist recent discov
inaccuraci data provid agenc iqvia nation sale perspect wholesale-level databas includ data
certain opioid product view sell-off level like overdon reflect continu busi risk fda
launch investig found iqvia data show drop kilogram fentanyl sold past five
year compar databas iqvia previous report fda determin steep drop due iqvia
overestim weight fentanyl fentanyl patch upon discoveri fda expand scope investig
found iqvia similar problem measur volum varieti drug includ opioid fda commission scott
gottlieb call upon iqvia immedi retain third-parti auditor conduct complet review data qualiti
minor dallianc thought ci/esrx
 express script merger proxi limit surpris consist expect healthcar servic
consolid posit view stand-alone prospect esrx
scenario think
activist bid
believ elliott offer take athena privat per share repres good opportun improv compani execut
gener attract return current public equiti sharehold
b-movi bad story-tel lead
miss opportun
attend analyst event host hope manag would present comprehens plan answer challeng
pharmaci retail instead manag reiter confid partnership strategi though acknowledg
evalu way transform busi model
maintain outperform rate share suspect va margin could come better expect recent
announc share repurchas plan could lead posit consensu revis
war word athena activist
morn elliott follow unsolicit offer take athena privat per share publicli pressur
athena bod initi sale process cite support sharehold research analyst financi media respons
athena issu statement state believ elliott character near-unanim sharehold approv
explor sale process accur board continu evalu option
result search floor
report result miss consensu ep estim profit growth remain challeng compani also
re-affirmed guidanc rang manag commentari emphasi diversif offer indic us core
market outlook weak
titl link note
qsii deliv strong result perhap importantli long-term investor healthi book growth view
first y/i book growth three year mileston indic health manag turnaround effort
take street management meet
increas convict cvs/aet thesi
host manag meet investor new york thursday came away increas convict around
strategi aetna transact likelihood deal close
dip april
sword anoth custom
make money move look
potenti netsmart sale
athn pressur mount pursu sale
iqvia wholesaler-level gener price data april show acceler volume-adjust deflat y/i
january/februari march simpl averag price per gener rx basi wholesal price per averag gener rx
vs deflat march april volume-adjust averag gener price lower march
volume-adjust brand inflat april deceler march slight neg wholesal
though note three wholesal much less profit exposur brand drug price increas make
figur less meaning gener volum increas y/i reflect fda emphasi acceler approv process
wellcar health plan mostli medicaid government-pay beneficiari use caremark pbm
announc acquisit meridian along meridian in-hous pbm meridianrx wellcar contract caremark
run suspect wellcar may look insourc pbm function point futur call
investor discuss acquisit wellcar manag said made decis acquisit may chang
mco/pbm relationship like option in-hous pbm note meridianrx
beneficiari meridian health custom member like would requir signific invest order develop
capabl need adequ serv wellcar beneficiari wellcar indic gener revenu
caremark although margin like well composit pbm margin estim wellcar exit caremark
relationship complet would annual op drag drag pf ep stand-alone
allscript manag recent suggest idea sell netsmart way unlock sharehold valu believ spin
netsmart could prove accret sharehold simplifi compani financi report could weigh growth
invest affili clearbridg invest own athena outstand share urg compani
offici explor potenti sale includ seek potenti financi strateg buyer letter board letter cite
excess execut turnov lack oper execut downward trajectori financi reason
exhibit us med-tech spec pharma coverag valuat tabl
note appli growth rate base number arriv data price bst may
pricemcapevev/salesforecast growthev ebitdaforecast growthpeforecast growthloc currencyloc compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate bax-ussector dickinson companybdx-ussector corporationbsx-ustop wmgi-usoutperform spec biomet itgr-ussector lifesci iart-ussector group hold trxc-usoutperform spec aray-ussector surgic isrg-ussector medic systemsvar-ussector ops-caoutperform spec riskcad tos-casector perform spec riskcad med-tech pharmaacelrx pharmaceut acrx-usoutperform spec therapeuticsagrx-usoutperform spec akrx-ussector depo-ussector perform spec pharmaceut endp-ussector therapeuticsflxn-usoutperform spec therapeuticsinsy-usoutperform spec pharmaceut spec therapeuticsgud-caoutperformcad spec prgo-ussector performila spec pharma exhibit us biotech coverag valuat tabl
price bst may
pricemcapevev/salesforecast growthforecast growthforecast growthloc currencyloc compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate vrx-ussector perform dvax-usoutperform spec risk sino-usoutperform spec risk ptct-ussector perform nologypbyi-ussector perform spec risk srpt-usoutperform onc-caoutperform spec riskcad nvln-ussector perform spec risk life scienc pli-caoutperform spec riskcad saabvx-froutperform spec risk saup-caoutperform spec riskcad once-usoutperform spec risk abeo-usoutperform spec risk biopharmaceuticalsaldr-usoutperform perform sbcrx-usoutperform spec risk na na na biib-ussector perform celg-ustop pick senta-ussector perform nvglpg-nlsector perform sciencesgild-usoutperform design imdz-usoutperform spec risk corporationincy-usoutperform sicpt-usoutperform therapiesitci-usoutperform spec risk kpti-usoutperform spec risk mrus-ussector perform spec risk pti-usoutperform spec risk sage-usoutperform svrtx-usoutperform pharmaxlrn-ussector perform sagio-usoutperform aimt-usoutperform spec risk akba-ussector perform salxn-usoutperform amgn-ussector perform perform spec risk atnx-usoutperform bmrn-ussector perform oncolog clvs-usoutperform prime fprx-usoutperform spec risk saobsv-usoutperform spec risk prta-ussector perform spec risk srarx-usoutperform spec risk sregn-ussector perform geneticssgen-usoutperform perform ebitdap exhibit us healthcar servic healthcar technology/distribut coverag valuat tabl
note dr aet evhc knd lhc qhc qsii appli growth rate base number arriv data price bst may
